Revolution Medicines logo

Revolution MedicinesNASDAQ: RVMD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

13 February 2020

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$9.15 B
0%vs. 3y high
92%vs. sector
-vs. 3y high
-vs. sector
-3%vs. 3y high
85%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 22:25:32 GMT
$54.75+$0.36(+0.66%)

Dividend

No data over the past 3 years
$750.00 K$750.00 K

Analysts recommendations

Institutional Ownership

RVMD Latest News

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
globenewswire.com25 October 2024 Sentiment: POSITIVE

First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
globenewswire.com23 October 2024 Sentiment: POSITIVE

Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October 25 at 12:00 p.m. Eastern Time (ET) REDWOOD CITY, Calif.

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
globenewswire.com21 October 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, in patients with previously treated, metastatic pancreatic ductal adenocarcinoma (PDAC).

Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: POSITIVE

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Steve Kelsey - President of R&D Wei Lin - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Chris Shibutani - Goldman Sachs Eliana Merle - UBS Alec Stranahan - Bank of America Kelly Shi - Jefferies Jay Olson - Oppenheimer Laura Prendergast - Raymond James Joseph Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to Revolution Medicine's Q2 2024 Earnings Conference Call.

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
globenewswire.com31 July 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
globenewswire.com11 July 2024 Sentiment: POSITIVE

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC)

Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
zacks.com10 July 2024 Sentiment: POSITIVE

Revolution Medicines (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
globenewswire.com08 July 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. Speakers will include members of Revolution Medicines' management team, along with Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard Medical School, and director of the Gastrointestinal Cancer Center and Robert T. & Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)
prnewswire.com08 July 2024 Sentiment: NEGATIVE

NEW YORK , July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Revolution Medicines, Inc. (NASDAQ: RVMD) on behalf of the company's shareholders. The investigation seeks to determine whether Revolution Medicines's directors breached their fiduciary duties in connection with recent corporate actions.

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research26 February 2024 Sentiment: NEGATIVE

Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.63 per share a year ago.

  • 1(current)

What type of business is Revolution Medicines?

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

What sector is Revolution Medicines in?

Revolution Medicines is in the Healthcare sector

What industry is Revolution Medicines in?

Revolution Medicines is in the Biotechnology industry

What country is Revolution Medicines from?

Revolution Medicines is headquartered in United States

When did Revolution Medicines go public?

Revolution Medicines initial public offering (IPO) was on 13 February 2020

What is Revolution Medicines website?

https://www.revmed.com

Is Revolution Medicines in the S&P 500?

No, Revolution Medicines is not included in the S&P 500 index

Is Revolution Medicines in the NASDAQ 100?

No, Revolution Medicines is not included in the NASDAQ 100 index

Is Revolution Medicines in the Dow Jones?

No, Revolution Medicines is not included in the Dow Jones index

When was Revolution Medicines the previous earnings report?

No data

When does Revolution Medicines earnings report?

The next expected earnings date for Revolution Medicines is 06 November 2024